Requirement of gut mucosal pDCs for establishing oral tolerance to prevent undesirable allergic reactions.
Background: Exposure to dietary constituents through the mucosal surface of the gastrointestinal tract generates oral tolerance that prevents deleterious T cell-mediated immunity. Although oral tolerance is an active process that involves emergence of CD4 1 forkhead box p3 (Foxp3) 1 regulatory T (Treg) cells in gut-associated lymphoid tissues (GALTs) for suppression of effector T (Teff) cells, how antigen-presenting cells initiate this process remains unclear. Objective: We sought to determine the role of plasmacytoid dendritic cells (pDCs), which are known as unconventional antigen-presenting cells, in establishment of oral tolerance. Methods: GALT-associated pDCs in wild-type mice were examined for their ability to induce differentiation of CD4 1 Teff cells, and such generation requires an autocrine loop of TGF-b for its robust production. A deficiency of pDCs abrogates antigen-specific de novo generation of CD4
1 Foxp3 1 Treg cells occurring in GALT after antigenic feeding. Furthermore, the absence of pDCs impairs development of oral tolerance, which ameliorates the progression of delayed-type hypersensitivity and systemic anaphylaxis, as well as allergic asthma, accompanied by an enhanced antigen-specific CD4 1 Teff cell response and antibody production. Conclusion: pDCs are required for establishing oral tolerance to prevent undesirable allergic responses, and they might serve a key role in maintaining gastrointestinal immune homeostasis. (J Allergy Clin Immunol 2018;141:2156-67.)
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Dendritic cells (DCs) are considered unrivaled essential antigen-presenting cells (APCs) that play critical roles in orchestrating the immune system, linking innate information to tailored adaptive responses. [1] [2] [3] DCs serve as sentinels, recognizing the presence of invading pathogens through various pattern recognition receptors to secrete multiple cytokines for induction of inflammatory responses, and they subsequently initiate primary T-cell responses on activation. [1] [2] [3] DCs comprise heterogeneous subsets that are functionally classified into classical or conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs). [1] [2] [3] Even at steady state, cDCs have outstanding capacity to prime naive T cells to generate various types of effector T (Teff) cells because of the prominent expression of MHC class II and costimulatory molecules. [4] [5] [6] On the other hand, pDCs constitute a distinct group of APCs specialized in endosomal Toll-like receptor (TLR) 7/9-mediated recognition of viral and self nucleic acids and respond with the massive secretion of type I interferon. 7, 8 Therefore pDCs have been not only been considered important mediators of antiviral responses 7, 8 but also contributors as primary inflammatory cells to the induction of pathogenesis in patients with psoriasis and systemic lupus erythematosus. [9] [10] [11] [12] Conversely, DCs might also be important for maintenance of immune homeostasis by promoting immune tolerance. 13, 14 It has been proposed that DCs not only participate in thymic clonal deletion of self-reactive T cells, which is known as central tolerance, but also induce peripheral tolerance mediated through clonal deletion and anergy of antigen-specific T cells and active immune suppression by CD4
1 forkhead box p3 (Foxp3) 1 regulatory T (Treg) cells, which encompass self-reactive thymus-derived naturally occurring Treg cells and inducible regulatory T (iTreg) cells generated from antigen-specific naive CD4 
Foxp3
2 T cells in the periphery. 13, 14 The gastrointestinal immune system is the largest and most complex part of the immune system, in which the gastrointestinal tract is exposed constantly to an enormous variety of foreign materials that might be either harmful or beneficial to the organism. 15, 16 Consequently, the gastrointestinal immune system has to balance protective immune responses to potentially pathogenic microorganisms with immunologic nonresponsiveness to commensal flora and dietary constituents to maintain mucosal immune homeostasis in this environment, a phenomenon known as oral tolerance. 15, 16 Oral tolerance is a physiologic process that prevents development of local and systemic deleterious T cellmediated inflammatory responses to commensals and dietary proteins. 15, 16 However, disruption of this process is believed to contribute to mucosal inflammation, leading to the occurrence of enteropathy, such as inflammatory bowel diseases and food allergies, as reflected by susceptibility genes and environmental factors. [17] [18] [19] Accumulating evidence supports a pivotal role for CD4 1
1 iTreg cells emerging from gut-associated lymphoid tissue (GALT) in enforcing oral tolerance, which requires antigen presentation by CD103 1 cDCs in the lamina propria (LP) of the small and large intestines and migration to the mesenteric lymph nodes (MLNs) after sampling antigen; these are privileged sites in triggering oral tolerance. [20] [21] [22] [23] These mucosal CD103
1 cDCs imprint characteristic features to favor generation of CD4 
1 iTreg cells relative to other cDC subsets in lymphoid and peripheral tissues under homeostatic conditions, including the preferential production of retinoic acid (RA), TGF-b, and indoleamine 2,3-dioxygenase (IDO), as well as prominent expression of the B7 family of costimulatory molecules (B7-H1 and B7-DC). [20] [21] [22] [23] On the other hand, pDCs have reportedly conferred peripheral tolerance to certain types of immunopathogenesis through suppression of pathogenic T-cell responses through mechanisms involving expansion of CD4 (Fig 1, C and D) or development of oral tolerance remains associative. Here we report that gastrointestinal pDC-mediated tolerogenesis through de novo generation of CD4 1
1 iTreg cells affects induction of oral tolerance, leading to abortive allergic responses.
METHODS
Comprehensive details about mice, 8, 12, 20 cell isolation and stimulation, 8, 19 flow cytometry, 6, 8, 19 quantitative RT-PCR, 19 antigen presentation assay, cytokine detection, in vitro CD4
1 T-cell differentiation assay, 6, 20 induction of oral tolerance and immunization with ovalbumin (OVA), adoptive transfer, measurement of serum OVA-specific antibody titers, delayed-type hypersensitivity (DTH) and systemic anaphylaxis to OVA, 28 airway inflammation to OVA, 29, 30 histopathologic assessment, 12 and statistical analysis are provided in the Methods section in this article's Online Repository at www.jacionline.org.
RESULTS

Characterization of mucosal pDCs in the gastrointestinal tract
Relative to cDCs, the features of mucosal tissue pDCs remain to be determined. [20] [21] [22] [23] Therefore we first compared cell-surface expression of various molecules on pDCs expressing Siglec-H and BST-2 in spleens, MLNs, and lamina propria of the small intestine (siLP) in wild-type. MLN pDCs displayed a higher expression of MHC class II (I-A/I-E) and CXCR3, as well as a4b7 and CCR9, which are known as gut-homing receptors, 19 whereas they exhibited lower expression of CD40, CD80, CD86, B7-H2, BST2, and CCR2 than splenic pDCs (see Fig E1 in this article's Online Repository at www.jacionline.org). On the other hand, siLP pDCs had higher or lower expression levels of CD86, B7-H1, B7-H2, and CD69, which are known as activation-inducing molecules, 19 and CD103 or CD40, CD80, I-A/I-E, BST2, CXCR3, and CCR9 when compared with splenic pDCs (see Fig E1) .
We next addressed the capacity of mucosal pDCs to prime naive CD4
1 T cells to differentiate CD4 
Foxp3
EGFP2 T cells was lower than that of their splenic counterparts (Fig 1, A and  B) . Similarly, MLN pDCs displayed a reduced capacity to generate antigen-specific IFN-g-producing KJ1-26 1 CD4 1 T cells (T H 1 cells) in the presence of IL-12 compared with splenic pDCs (Fig 1, C and D) . On the other hand, MLN pDCs showed a slightly higher induction of antigen-specific IL-17-producing KJ1-26
1
CD4
1 T cells (T H 17 cells) in the presence of TGF-b plus IL-6 than splenic pDCs (Fig 1, E and F) .
We also compared the potential of pDCs to induce differentiation of CD4 1
Foxp3
2 T cells into CD4 
CD4
1 Foxp3 EGFP2 T cells when compared with splenic pDCs in the presence of sufficient TGFb, whereas the addition of RA further promoted their generation (Fig 1, G and H (Fig 2, A) , which were regulated differently in cDCs. 32 Because the autocrine loop of TGF-b was observed reportedly in some tumor cells and cDCs, 32 we examined autoregulation of TGF-b in pDCs. On stimulation with TGF-b, splenic pDCs and MLN pDCs elicited TGF-b production at similar levels (Fig 2,  A and B) .
To clarify the importance of the autocrine loop of TGF-b in the generation of CD4 (Fig 2, C and D) , which was similar to that seen under TGF-b-insufficient conditions (see Fig E2) , probably because of similar concentrations of TGF-b in the culture. Furthermore, the ability of MLN pDCs to generate antigen-specific CD4 (Fig 2, A) and TGF-b production (Fig 2, B) were measured. Data were obtained tryptophan or mAbs to B7 family members of costimulatory molecules had no substantial effect on the capacity of MLN pDCs to induce antigen-specific CD4 
Foxp3
1 iTreg cells in vivo and oral tolerance by using myeloid lineage-specific APC depletion in mice. 23 To clarify how pDCs contribute to de novo generation of CD4 
1 iTreg cells to establish oral tolerance, we used Siglech dtr/1 mice, 8, 12, 19 which harbor expression of the diphtheria toxin (DT) receptor under the control of the Siglech gene, allowing almost complete and specific elimination of Siglec-H 1 pDCs in mucosal lymphoid tissues, including MLNs and siLP, as well as the spleen, using DT treatment (Fig 3, A-D; referred to as pDCablated mice).
To clarify the role of pDCs in antigen-specific differentiation of CD4 
EGFP2 T cells into mice, fed these mice OVA protein, and monitored the generation of KJ1-26
EGFP1 iTreg cells in spleens and MLNs. OVA-fed mice displayed a dramatic generation of KJ1-26
EGFP1 iTreg cells in MLNs compared with nonfed mice, whereas little or no induction was observed in spleens (Fig 3, E-G) . In contrast, pDC-ablated mice exhibited a reduction in generation of these iTreg cells in MLNs after OVA protein feeding (Fig 3, E- 
1 iTreg cells in GALT after antigenic feeding.
Requirement of pDCs to establish oral tolerance, leading to abortive allergic responses
Because oral tolerance is largely dependent on generation of CD4 1
Foxp3
1 iTreg cells in GALT, [20] [21] [22] [23] we investigated induction of oral tolerance in mice deficient in pDCs. OVA-fed mice manifested typical features of oral tolerance, including suppression of OVA-specific IgG 1 production and reduced activation of antigen-specific CD4 1 T cells and their production of IFN-g, as well as impaired generation of T H 1 cells after recalled stimulation with OVA protein, compared with values seen in nonfed mice when mice were fed OVA protein before systemic immunization with OVA protein emulsified in complete Freund adjuvant (CFA; Fig 4) . In contrast, OVA-fed mice with deficiency in pDCs did not experience oral tolerance (Fig 4) Because oral tolerance is supposed to be used as a strategy for preventing local and systemic T cell-mediated inflammatory disorders, such as allergic reactions, 16 we assessed the requirement of pDCs in the process of oral tolerance to prevent T H 1-mediated allergic responses. OVA-fed mice exhibited a reduction in the progression of DTH indicated as ear swelling in response to intradermal sensitization with OVA protein after systemic immunization with OVA protein plus CFA compared with that seen in nonfed mice, whereas ablation of pDCs inhibited this suppressive effect on DTH response in OVA-fed mice (Fig 5, A-C) . Although intraperitoneal sensitization with OVA protein caused systemic anaphylaxis marked in the decrease in body temperature after systemic immunization with OVA protein plus CFA, OVA protein feeding before systemic immunization ameliorated this systemic anaphylactic response (Fig 5, D-F) . In contrast, elimination of pDCs impaired this protective effect on systemic anaphylaxis to OVA protein in OVA-fed mice (Fig 5, D-F) .
In addition, we addressed the contribution of pDCs to the development of oral tolerance protecting against T H 2-mediated allergic airway responses. Systemic immunization with OVA protein emulsified in aluminum hydroxide elicited typical T H 2 responses, including production of OVA-specific IgG 1 and IgE and activation of antigen-specific CD4
1 T cells and their production of IL-4, as well as generation of IL-4-producing T H 2 cells on recalled stimulation with OVA protein (see Fig E7 in this article's Online Repository at www.jacionline.org). Furthermore, these mice exhibited asthmatic symptoms with augmentation of airway hyperresponsiveness to methacholine (Fig 6, A and B) , increased cellular infiltrates in bronchoalveolar lavage fluid (BALF) with eosinophilia (Fig 6, C) , and histologic lung inflammation with abundant inflammatory cell infiltration and mucus deposition in the airway walls (Fig 6, D) after intranasal sensitization with OVA protein. On the other hand, OVA-fed mice with oral tolerance showed marked amelioration of these T H 2 responses and allergic pathogenesis compared with nonfed mice (Fig 6 and  see Fig E7) . However, the deficiency in pDCs partly abrogated from 3 individual samples in a single experiment. *P < .01 compared with untreated control (PBS). C-J, pDCs obtained from spleens (Fig 2, C and D) and MLNs (Fig 2, C-J) were stimulated or not with TGF-b in the presence or absence of control IgG (Fig 2, E and F) , anti-TGF-b mAb (Fig 2, E and F) , TGF-b receptor I/II inhibitor (Fig 2, G and H) , or methyl-DL-tryptophan (Fig 2, I and J) , and KJ1-26 1 CD4
1 Foxp3 EGFP2 T cells were cultured with or without pDCs in the presence of RA and OVAp. Cell-surface expression profile (Fig 2, C , E, G, and I) and proportion (Fig 2, D, F the development of oral tolerance to protect against a T H 2-mediated allergic inflammation in OVA-fed mice (Fig 6 and see  Fig E7) .
Collectively, these results indicate that the absence of pDCs impairs the protective effect of oral tolerance on T H -driven allergic immunopathogenesis.
DISCUSSION
Although recent accumulating results suggest that the existence of mucosal tissue-associated cDC subsets is a link to the dietary antigen-mediated emergence of CD4 1
Foxp3
1 iTreg cells and development of oral tolerance, [20] [21] [22] [23] the characteristics and function of pDCs located in GALT for initiating these processes remain elusive. We show here the possible prerequisite role of pDCs in de novo conversion of CD4 1 Foxp3 2 T cells to CD4 1
1 iTreg cells in GALT mediated through an autocrine loop of TGF-b to establish oral tolerance, thereby leading to protection against T H cell-mediated inflammatory allergic disorders.
Although expression of a4b7, CCR9, and/or CD103 is reported on the majority of GALT-associated leukocytes, such as subsets of T cells and cDCs, both MLN and siLP pDCs, as well as splenic pDCs, constitutively expressed these gut-homing receptors at various levels. In addition, siLP cDCs displayed different expression patterns of CCR2 and CXCR3, as well as these gut-homing receptors, compared with their counterparts in spleens and MLNs. In contrast to peripheral pDCs, which accumulate in lymph node tissues, with their transit time regulated by lysophospholipid sphingoshine-1-phosphate receptor-dependent trafficking under homeostatic conditions and during viral infection, GALT-associated pDCs can mobilize into the intestinal LP through hematogeneous mobilization rather than lymphatic trafficking, and they can mobilize into the MLNs through blood and lymphatic vessels under homeostatic and mucosal inflammatory conditions. 19 Therefore distinct expression patterns of gut-homing receptors of cell adhesion molecules and chemokine receptors might reflect the trafficking and localization of circulatory and tissue-resident pDCs.
Although pDCs have been known as poor APCs compared with cDCs in peripheral lymphoid tissues, 8 MLN pDCs were even less efficient for proliferation of naive CD4 1 T cells than splenic pDCs because of the lower expression of costimulatory molecules (eg, CD40, CD80, and CD86). These results suggest that GALTassociated pDCs function as tolerogenic APCs to inhibit activation of CD4 1 T cells against dietary and commensal antigens in the gastrointestinal tract and to avoid undesirable CD4
1 Teff cell-mediated intestinal immune pathogenesis.
Relative to the better understanding of the hierarchy of cDC subsets in peripheral and mucosal tissues in the induction of CD4 
1 iTreg cells mediated through several molecular pathways, [20] [21] [22] [23] the potential ability of pDCs and the mechanism for eliciting the conversion of CD4 
1 iTreg cells from naive CD4
1
Foxp3
2 T cells has been less defined. Analysis of CD4
1 T-cell differentiation in vitro using a genetic reporter system revealed that MLN pDCs had a higher capacity to induce antigen-specific CD4 1
1 iTreg cells than splenic pDCs under TGF-b-sufficient conditions, whereas they exhibited comparable generation under TGF-b-insufficient conditions, suggesting that the TGF-b-dependent context affects their potential ability to generate to antigen-specific CD4 
1 iTreg cells. Concomitantly, experiments using blocking mAbs and inhibitor showed that B7-H1 and B7-DC, as well as IDO, were dispensable for this function of MLN pDCs. On the other hand, the exposure of MLN pDCs to TGF-b triggered its production, and the blockade of TGF-b signaling abrogated their function for generation of antigen-specific CD4 1
1 iTreg cells. Taken together, these results suggest that a TGF-b-enriched milieu provided by epithelial cells 32 and cDCs 32 sensing commensals in the gastrointestinal tract drives the autocrine loop of TGF-b in GALTassociated pDCs and facilitates the preferential de novo generation of antigen-specific CD4 1
1 iTreg cells, which are amplified by secretion of RA in this microenvironment.
Previously, we have shown that costimulation through CD80/CD86:CD28 abrogated the ability of cDCs to induce CD4 1 Foxp3 1 iTreg cells, whereas it enhanced their generation of T H 1 cells. 20 On the other hand, it has been shown that IL-2 promoted T H 1 differentiation, whereas it repressed T H 17 differentiation. 33 MLN pDCs had a higher or lower capacity to drive differentiation of antigen-specific T H 17 cells and CD4
1 Foxp3 1 iTreg cells in the presence of sufficient TGF-b or T H 1 cells than splenic pDCs. Furthermore, they exhibited a lower expression of CD80/CD86 and activation of CD4
1 T cells to produce IL-2 than splenic counterparts. Collectively, these phenomena imply that the difference in the ability to generate CD4
1 Teff cells and CD4
1
Foxp3
1 iTreg cells between splenic and MLN pDCs is reflected by the distinct context of costimulation through CD80/CD86:CD28 and IL-2 secretion, as well as RA production.
Although previous studies have addressed the role of pDCs in the development of oral tolerance by using mAb to BST-2 for pDC depletion, 26, 27 this approach remains problematic because this molecule is constitutively expressed on other immune cells, especially in intestinal lymphoid tisues, 19 resulting in depletion of additional cell types and hampering characterization of the intrinsic function of pDCs in the initiation of this process. To bypass such limitations, we used gene-modified mice with selective elimination of pDCs, among which they had normal constituencies of other immune cells in GALT in accordance with the published reports. 8, 12, 19 Therefore use of this system could provide an advantageous means to precisely evaluate the contribution of pDCs to the induction of CD4 1 Foxp3 1 iTreg cells and oral tolerance.
Much attention has been paid to the function of cDCs for differentiation into CD4
1 Foxp3 1 iTreg cells in vivo during development of oral tolerance, [20] [21] [22] [23] but far less is known about the role of pDCs in the program for the development of these cells. Our results clearly showed that generation of antigen-specific CD4 
1 iTreg cells in MLNs was diminished markedly in the absence of pDCs after oral antigen feeding. These results suggest the essential contribution of pDCs to mucosal generation of antigen-specific CD4 
1 iTreg cells after oral antigen exposure.
Although we show that specific elimination of pDCs led to abrogation of the development of oral tolerance indicated by the inhibition of antigen-specific production of IgG 1 
and CD4
1 Teff cell responses by approximately 40% and 60%, respectively, the mAb-mediated systemic depletion of BST2 1 cells caused the almost complete prevention of this process, as demonstrated by inhibition of hapten-specific CD8 1 T cells mediating contact hypersensitivity. 26, 27 This indicated that using anti-BST2 mAb could lead to apparent overestimation of pDC function for inducing oral tolerance because of depletion of additional cell types. On the other hand, reconstitution with antigen-specific CD4 1
Foxp3
1 Treg cells achieved near-complete restoration of the state of oral tolerance in the absence of pDCs. Taken together, these findings suggest an essential role of pDCs for establishing oral tolerance meditated through de novo generation of antigen-specific CD4 (Fig 3, A) and proportion (Fig 3, B-D (Fig 3, A and B) , MLNs (Fig 3, A and C) , and siLP (Fig 3, A and D) in Siglech dtr/1 mice that had been treated with PBS or DT (n 5 5 per group). Data were obtained from 3 individual samples in a single experiment. *P < .01 compared with PBS. E-G, KJ1-26 1 CD4 1 Foxp3 EGFP2 T cells were transferred into Siglech dtr/1 mice that had been treated with PBS or DT, and the animals were subsequently fed PBS or OVA protein (n 5 5 per group). Cell-surface expression profile (Fig 3, E) and proportion (Fig 3, F and G (Fig 3, E and F) and MLNs (Fig 3, E and G) on day 5 after adoptive transfer are shown. Data were obtained from 3 individual samples in a single experiment. *P < .01 compared among groups. All data are representative of at least 3 independent experiments. Spl, Spleen. Siglech dtr/1 mice that had been treated with PBS or DT were fed PBS or OVA protein and then systemically immunized with OVA protein 7 days after oral priming (n 5 5 per group). Subsequently, serum and splenic CD4 1 T cells were collected from mice 14 days after systemic immunization. A, Serum OVA-specific IgG 1 production. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. B-F, OVA-specific production of IL-2 (Fig 4, B) and IFN-g (Fig 4, C) by CD4 1 T cells. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. Intracellular expression profile (Fig 4, D) and proportion (Fig 4, E and F) of CD4 1 IFN-g 1 T cells (Fig 4, D and E) and CD4
1 IL-4 1 T cells (Fig 4, D and F) are shown. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. All data are representative of at least 3 independent experiments. Spl, Spleen. Siglech dtr/1 mice that had been treated with PBS or DT were fed PBS or OVA protein and then systemically immunized with OVA protein 7 days after oral priming (n 5 5 per group). A-C, At 10 days after systemic immunization, the left or right ear of mice was sensitized with OVA protein or PBS. Fig 5, A, OVA-specific DTH was determined based on ear thickness. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice immunized with OVA protein. Fig 5, (Fig 5, E) and indicated (Fig 5, F) 60 minutes after sensitization. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice immunized with OVA protein or among groups. All data are representative of at least 3 independent experiments.
Mucosal tolerance is suggested to prevent pathologic reactions against dietary and environmental antigens, as well as intestinal flora, and its failure is believed not only to contribute to exacerbated gastrointestinal inflammation, such as inflammatory bowel disease and food allergies, but also to affect the occurrence and severity of local and systemic T cell-mediated inflammation, including autoimmune and allergic diseases. [15] [16] [17] [18] We showed that the absence of pDCs during the development of oral tolerance aggravated pathogenic CD4
1 Teff cellmediated allergic responses, which had a slightly more mild effect than CD4
1 Teff cell responses. Although the precise reason for this disconnect between induction of CD4 1 Teff cell responses and their sequelae remains unclear, the observed slight discrepancy might be due to the defect in oral tolerance to inhibit the T cell-independent pathogenic inflammatory responses.
Collectively, these results suggest that pDCs critically confer oral tolerance to dampen systemic CD4
1 Teff cell-driven allergic immunopathogenesis. Conceivably, these phenomena imply that a functional defect in GALT-associated pDCs might be involved in failure to establish oral tolerance, causing these immunopathologies because a malfunction in peripheral pDCs leads to exacerbation of lupus-like disease. 12 Further study will be needed to examine this possibility.
In conclusion, we report the need for authentic tolerogenic function of pDCs for de novo generation of antigen-specific CD4 1
1 iTreg cells in GALT and to establish oral tolerance that prevents deleterious CD4
1 Teff cell-mediated inflammatory allergic disorders, and therefore they are instrumental in controlling gut mucosal immune homeostasis. In future studies, a better understanding of the nature of mucosal pDC-mediated tolerogenesis might open new avenues for exploring therapeutic strategies to mediate oral tolerance for inflammatory immune disorders and prevent intolerance to oral vaccines against infectious diseases.
We thank all members of the animal facility at the University of Miyazaki, Y. Sato and I. Goto for secretarial assistance, and Y. Kawagoe for technical help in cell sorting. Siglech dtr/1 mice that had been treated with PBS or DT were fed PBS or OVA protein and then systemically immunized with OVA protein 7 and 14 days after oral priming. Subsequently, mice were sensitized intranasally with OVA protein or PBS on days 7, 8, and 9 after the last immunization, and BALF and lung tissue were obtained at 10 days after the last immunization. A and B, Airway function was analyzed for changes in resistance of the respiratory system (R rs ) in response to increasing doses (Fig 6,  A; 3.125-50 mg/mL) or the indicated dose (Fig 6, B; 50 mg/mL) of inhaled methacholine. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. C, Absolute cell numbers of BALF cells. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. Eosino, Eosinophils; Leu, leukocytes; Mac, macrophages; Neu, neutrophils. D, Hematoxylin and eosin (HE) and periodic acid-Schiff (PAS) sections obtained from the lung at low-magnification (34) and higher magnification (310). Bars 5 100 mm. Arrow indicates mucus deposition. All data are representative of at least 3 independent experiments. 
METHODS Mice
The following 8-to 12-week-old female mice were used in this study. BALB/c mice used as wild-type mice were purchased from CLEA (Tokyo, Japan). Foxp3 EGFP DO11.10 OVA-specific TCR (KJ1-26 clonotype) transgenic BALB/c mice were generated by crossing Foxp3 EGFP C57BL/6 mice with DO11.10 OVA TCR transgenic BALB/c mice, E1 and they were further bred in-house with Rag2 2/2 DO11.10 OVA TCR transgenic BALB/c mice to obtain Foxp3 EGFP Rag2 2/2 DO11.10 OVA TCR transgenic BALB/c mice.
E1
B6.Siglech dtr/dtr mice, which express the DT receptor under the control of the Siglech gene, were generated, as described previously, E2 and deposited as B6.Cg-Siglech <tm1.1Ksat> mice in the RIKEN BioResource Center (accession no. RBRC05658). B6.Siglech dtr/dtr mice were cross-mated for more than 12 generations with BALB/c mice to obtain BALB/c background Siglech dtr/dtr homozygous mutant mice, E3 and they were also deposited as C.Cg-Siglech <tm1.1Ksat> mice in the RIKEN BioResource Center (accession no. RBRC09688).
For systemic ablation of pDCs, Siglech dtr/1 heterozygous mice were injected intraperitoneally with DT (1 mg per mouse; Sigma-Aldrich, St Louis, Mo) and used as pDC-ablated mice. In parallel experiments Siglech dtr/1 mice were injected intraperitoneally with PBS and used as pDC-sufficient control mice. All mice were bred and maintained in specific pathogen-free conditions in the animal facility at the University of Miyazaki, and all experiments were performed in accordance with institutional guidelines of the Animal Experiment Committee and Gene Recombination Experiment Committee.
Cell isolation and stimulation
Leukocytes were prepared from spleens, MLNs, and siLP, as described previously.
E2,E4 CD11c 1 DCs and BST2 1 pDCs were purified by using Auto-MACS with mouse CD11c (N418) Microbeads and a mouse pDC isolation kit II (both from Miltenyi Biotec, Bergisch Gladbach, Germany). 10 4 ) were cultured with or without recombinant human TGF-b1 (20 ng/mL; Wako Pure Chemicals, Tokyo, Japan), PGN (1 mg/mL; SigmaAldrich), LPS (1 mg/mL; Sigma-Aldrich), or CpG-B (1 mmol/L; Hokkaido System Science, Sapporo, Japan) for 6 or 48 hours in in 96-well roundbottom plates (BD Biosciences), and cells or culture supernatants were collected to detect transcriptional expression or cytokine production. 
Flow cytometry
Quantitative RT-PCR
Total RNA was extracted with TRIzol (Life Technologies, Grand Island, NY), and cDNA was synthesized with the PrimeScript RT reagent kit (Takara, Shiga, Japan). E4 Transcriptional expression levels were analyzed by using SYBR Premix Ex Taq II on Thermal Cycler Dice (Takara) with specific primer pairs for Tgfb1 (59-acc atg cca act tct gtc tg-39 and 59-cgg gtt gtg ttg gtt gta ga-39), Aldh1a2 (59-tgg gtg agt ttg gct tac gg-39 and 59-aga aac gtg gca gtc ttg gc-39), and Gapdh (59-aaa ttc aac ggc aca gtc aag-39 and 59-tgg tgg tga aga cac cag tag-39) after normalization for Gapdh expression. ) in the presence or absence of OVA protein (1 mg/mL; Sigma-Aldrich) for 3 days in 96-well flat-bottom plates (BD Biosciences). Cells and culture supernatants were collected to detect cytokine production.
Antigen presentation assay
Cytokine detection
Culture supernatants and sera were assayed for IL-2, TGF-b (eBioscience), IFN-g, and IL-4 (BioLegend) by using ELISA kits, according to the manufacturers' instructions.
In vitro CD4
1 T-cell differentiation assay 
Induction of oral tolerance and immunization with OVA
Mice were administered intragastrically with or without 50 mg of chicken OVA protein (A7642-1VL; Sigma-Aldrich) dissolved in PBS. Control mice were given PBS alone. One week after OVA feeding, mice were immunized subcutaneously with 100 mg of OVA protein emulsified in CFA (Difco). For pDC-ablated mice, Siglech dtr/1 mice were injected intraperitoneally with DT, as described above, on 1 day before OVA feeding and on day 3 after the start of the treatment. Two weeks after immunization, spleens and sera were obtained from the mice.
Adoptive transfer
Mice were injected intravenously with Rag2 per mouse) were injected intravenously into mice before subcutaneous immunization with 100 mg of OVA protein emulsified in CFA. Two weeks after immunization, spleens and sera were obtained from the mice.
Measurement of serum OVA-specific antibody titers
Serum OVA-specific IgG 1 and IgE were assayed by means of ELISA with a Mouse Anti-OVA-IgG 1 ELISA Kit and Mouse Anti-OVA-IgE ELISA Kit (Sibayagi, Gunma, Japan), according to the manufacturer's instructions.
DTH and systemic anaphylaxis to OVA
Mice fed with or without OVA protein were immunized subcutaneously with OVA protein emulsified in CFA, as described above. At 10 days after immunization, the left ear of each mouse was challenged by means of intradermal administration of 75 mg of OVA protein in 30 mL of PBS, and the right ear was administered an equal amount of PBS as a control by using a microsyringe (Lo-dose insulin syringe 0.3cc with 30 G; Becton Dickinson, Franklin Lakes, NJ). OVA-specific DTH was determined based on ear thickness at various days after challenge for 10 days by using digital calipers (PK-1012CPX; Mitutoyo, Kanagawa, Japan). For systemic anaphylaxis, mice fed with or without OVA protein were challenged by means of intraperitoneal administration with 100 mg of OVA protein on 10 days after immunization, and rectal temperature was measured with a digital thermometer (TD-300; Shibaura Electronics, Saitama, Japan) every 10 minutes from 5 minutes after challenge for 2 hours. E6 Alternatively, whole-body temperature was imaged 60 minutes after challenge by using a thermography device (Handy Thermo TSV-200 ME; Nippon Avionics, Tokyo, Japan).
Airway inflammation to OVA
On days 7 and 14 after OVA feeding, mice were immunized intraperitoneally with 20 mg of OVA protein emulsified in aluminum hydroxide (4 mg of Imject Alum; Thermo Scientific, Waltham, Mass). Subsequently, mice were challenged intranasally with 100 mg of OVA protein in 20 mL of PBS or PBS alone as a control on days 7, 8, and 9 after the last immunization. At 10 days after the last immunization, samples from the spleen, sera, BALF, and lung were obtained from the mice. E7 For measurement of airway responsiveness, airway function was analyzed for changes in resistance of the respiratory system in response to increasing doses of inhaled methacholine (3.125, 6.25, 12.5, 25 , and 50 mg/mL; Sigma-Aldrich) by using an invasive flexiVent (SCIREQ Scientific Respiratory Equipment, Montreal, Quebec, Canada).
E7,E8
Histopathologic assessment
Tissues from the ear and lung were fixed with 4% paraformaldehyde in PBS and embedded in paraffin. Tissue sections (5 mm thick) were stained with hematoxylin and eosin and periodic acid-Schiff. Stained slides were examined with bright-field microscopy (BX53; Olympus, Center Valley, Pa). Areas of the epidermis and dermis of the ear were quantified by thickness by using ImageJ software (National Institutes of Health, Bethesda, Md) by a blinded observer, as described previously.
E3
Statistical analysis
Data are expressed as means 6 SDs from 3 to 5 individual samples in a single experiment, and we performed at least 3 independent experiments. The statistical significance of the differences between the values obtained was evaluated by means of ANOVA. A P value of less than .01 was considered significant. 
CD25
2 Foxp3 EGFP1 or KJ1-26
1
CD25
1 Foxp3 EGFP2 T cells. Subsequently, mice were systemically immunized with OVA protein 7 days after oral priming (n 5 5 per group), and serum and splenic CD4
1 T cells were collected from mice 14 days after systemic immunization.
A, Serum OVA-specific IgG 1 production. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with OVA-fed mice in the absence of pDCs or among groups. B, OVA-specific production of IL-2 by CD4 1 T cells. Data were obtained from 5 individual samples in a single experiment.
*P < .01 compared with OVA-fed mice in the absence of pDCs or among groups. All data are representative at least 3 independent experiments.
FIG E7.
Specific elimination of pDCs impairs the protective effect of oral tolerance on allergic T H 2 responses. Siglech dtr/1 mice that had been treated with PBS or DT were fed PBS or OVA protein and then systemically immunized with OVA protein 7 and 14 days after oral priming. Subsequently, mice were sensitized intranasally with OVA protein or PBS on days 7, 8, and 9 after the last immunization (n 5 5 per group), and serum and splenic CD4
1 T-cell counts were obtained 10 days after the last immunization. A and B, Serum OVA-specific production of IgG 1 (Fig E7, A) and IgE (Fig E7, B) . Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. C-H, OVA-specific production of IL-2 ( Fig E7, C) , IFN-g (Fig E7, D) , and IL-4 ( Fig E7, E) by CD4 1 T cells. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. Intracellular expression profile (Fig E7, F) and proportion ( Fig E7, G and H) of CD4 1 IFN-g 1 T cells (Fig E7, F and G) and CD4 1 IL-4 1 T cells (Fig E7, F and H) are shown. Data were obtained from 5 individual samples in a single experiment. *P < .01 compared with nonfed mice or among groups. All data are representative of at least 3 independent experiments.
